However, this association easily reverses the causality bias, because stopping renin-angiotensin-aldosterone system inhibitor therapy when hyperkalemia occurs may increase the observed risk.
However, this association is prone to reverse causality bias, as stopping the treatment of renal-angiotensin-aldosterone system inhibitors when hyperkalemia occurs may increase the observed risk.
However, this association is likely to reverse the causal bias, as discontinuation of renin angiotensin aldosterone system inhibitor therapy at the onset of hyperkalemia may increase the observed risk.<br>